CWP
CHRS icon

Clark Wealth Partners’s Coherus Oncology CHRS Stock Holding History

Clark Wealth Partners’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-23
Closed -$17 – 583
2025
Q2 		$17 Hold
23
– – ﹤0.01% 532
2025
Q1 		$19 Hold
23
– – ﹤0.01% 522
2024
Q4 		$32 Buy
+23
New +$26 ﹤0.01% 518

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Clark Wealth Partners's CHRS Position: Q3 2025 in Review

Clark Wealth Partners sold out of Coherus Oncology (CHRS) in Q3 2025, closing a stake of 23 shares — an estimated $17 sold.

Clark Wealth Partners first reported a position in CHRS in Q4 2024 and held it in 3 quarters. The position peaked at $32 in Q4 2024. 114 funds tracked by Wall St. Rank hold CHRS as of Q3 2025.

  • Clark Wealth Partners reported no remaining Coherus Oncology position as of Q3 2025 after selling out during the quarter.
  • Clark Wealth Partners sold 23 Coherus Oncology shares in Q3 2025, an estimated $17.
  • Clark Wealth Partners first reported a position in Coherus Oncology in Q4 2024 and held it in 3 quarters.
  • Clark Wealth Partners's Coherus Oncology position peaked at $32 in Q4 2024.
  • 114 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2025.

Based on Clark Wealth Partners's 13F filing for Q3 2025, filed 4 Feb 2026.